Severity Over Time of Early Forms of Spondyloarthritis
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS
About this trial
Spondyloarthritis (SpA) is a group of chronic inflammatory pathologies whose progression over time is poorly defined, and in particular the clinical and instrumental elements that can predispose to a condition of disease severity are not completely known. It would be important to have an idea of what the predisposing factors are, possibly already at baseline, and possibly also at follow up, of severe disease, so as to be able to act early with more aggressive and targeted therapies on these patients, so as to achieve remission.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
age >18 years;
Diagnosis of SpA confirmed by the rheumatologist with duration of symptoms <
2 years;
Signature of the written informed consent to the study
Disqualifiers
Age < 18 years;
Patients suffering from other rheumatic pathologies (even in overlap), or genetic diseases such as Marfan syndrome, Ehlers Danlos syndrome
Any medical or psychiatric condition that in the judgment of the investigator would prevent the participant from complying with the protocol or completing the study according to the protocol.
Refusal to sign the informed consent to the study.
Trial population
patients with recent onset of SpA (duration of symptoms ≤2 years) and diagnosis made by the rheumatologist.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Diagnostic assessment
Diagnostic testpatient with sponiloarthritis who comes to the clinic Hospital for clinical evaluation of disease. Assessment instrumental evaluation of the axial involvment t, with x-ray of the spine and pelvis every 5 years, and MRI of the spine and pelvis every 2 years.
Diagnostic assessment
Diagnostic testperipheral involvement, with joint ultrasound at baseline, at 3 months from the start of a new therapy, and therefore in the event of reactivation of the disease
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
spondyloarthritis severity
evaluation of disease severity at 10 years in the entire study population
Time frame
t0 baseline 3hours, t1 3 months 3hours,t2 6 months 3hours,t2 12months 3hours,every six months up to the tenth yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: